Leap Therapeutics

Leap Therapeutics (Nasdaq: LPTX) is a publicly traded clinical stage oncology company. Their lead drug candidate, DKN-01, is a monoclonal antibody that targets DKK1 expressing tumors in multiple indications including gastric, prostate, endometrial, colorectal, and lung cancers.

Referred to us by our colleagues at Argot Partners, Leap Therapeutics had an aggressive timeline. They needed a new investor presentation deck and company website in time for the approaching JP Morgan Healthcare Conference.

Working with CEO Doug Onsi and his team we gained a thorough understanding of the company and its’ science. Using that information, we created a new corporate story that explains their science and programs in a clearer way. The new website communicates their message and therapy with rich graphics and animations. It continues to pitch Leap’s value around-the-clock and complements their investor deck by providing a cohesive brand experience.

As Leap Therapeutics grows and their pipeline’s clinical trials progress we continue to support them by updating their deck and website as new clinical trials, data, and needs arise.

This slide from Leap Therapeutics provides a company overview, highlighting their focus as a clinical-stage oncology company developing DKN-01, a monoclonal antibody targeting the DKK1 protein. It illustrates potential applications of DKN-01 in various cancers like endometrial cancer (with paclitaxel), gastric/GEJ adenocarcinoma (with anti-PD-1 tislelizumab and chemo), and prostate cancer (with docetaxel).
This slide from Leap Therapeutics illustrates how DKK1 expression is determined using RNAscope, showing examples of low and high DKK1 patient samples and explaining the methodology. This supports the rationale for targeting DKK1 in specific patient populations.
This illustration details how DKN-01, Leap Therapeutics' anti-DKK1 antibody, binds to and removes free DKK1 from the tumor microenvironment (TME). It depicts the downstream effects, including reduced cell proliferation and angiogenesis, suppression of MDSC cells, and activation of NK cells.
This slide from Leap Therapeutics explains the combined effect of DKN-01 and anti-PD1 therapy. It details how DKN-01 stimulates the innate immune system (NK cells, pro-inflammatory TME, upregulating PD-L1) and how anti-PD1 stimulates CD8 T cell adaptive immunity.
A visual from Leap Therapeutics highlighting the development of DKN-01 for esophagogastric cancer. It features an image of an individual and a purple ribbon, often associated with cancer awareness.
A visual from Leap Therapeutics highlighting the development of DKN-01 for esophagogastric cancer. It features an image of an individual and a purple ribbon, often associated with cancer awareness.
This graphic illustrates the role of DKK1 in cancer, explaining how it is produced by cancer cells and functions on various tumor pathways and nearby immune cells, affecting angiogenesis, cell proliferation, MDSC cells, and NK cells. This comes from Leap Therapeutics to explain the rationale for targeting DKK1 with DKN-01.
A view of the Leap Therapeutics homepage on different devices (laptop, tablet, mobile), with the tagline 'Stopping cancer requires new therapies and new combinations' and featuring information about DKN-01 as an anti-DKK1 antibody.
Responsive website design for Leap Therapeutics showcasing their clinical pipeline on different devices (laptop, tablet, mobile). It lists their programs, including DKN-01 in various cancer indications.
This image shows how the mechanism of action of DKN-01 is presented on Leap Therapeutics' responsive website across different devices. It likely includes illustrations detailing its effects on the tumor microenvironment.